Heterozygous Variant of CYP2C8∗3 is a Protective Factor for Developing Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Mike J.P. de Jong(Radboud University Nijmegen), Erwin-Jan M. van Geenen(Radboud University Nijmegen), R K W Kuipers(Radboud University Nijmegen), Tanya M. Bisseling(Radboud University Nijmegen), Marco J. Bruno(Erasmus MC), Niels G. Venneman(Medisch Spectrum Twente), Christina J. Sperna Weiland(Radboud University Nijmegen), Foke van Delft(Maine Farmland Trust), Muhammed Hadithi(Gaustad Hospital), R.H. te Morsche(Radboud University Nijmegen), Joost P H Drenth(Radboud University Nijmegen), Peter D. Siersema(Radboud University Nijmegen), Robert C. Verdonk(St. Antonius Ziekenhuis)
Clinical Gastroenterology and Hepatology
December 14, 2024
10.1016/j.cgh.2024.10.024
Cited by 1

Related Papers

International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer
|Gut|2012|776
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
United European Gastroenterology evidence‐based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU)
|United European Gastroenterology Journal|2017|698
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium
|Gut|2019|620
Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial
|˜The œLancet. Gastroenterology & hepatology|2019|597